Oncolytics Biotech® Inc. is conducting clinical trials with the objective of developing REOLYSIN® as a human cancer therapeutic.

This clinical program is designed to identify targets for late-stage registration trials with REOLYSIN®, the first of which is a Phase III combination REOLYSIN® and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers.

* REOLYSIN® is a registered trade mark owned by Oncolytics Biotech Inc. and is registered in Canadian and US Trade Mark offices.